Lobaplatin induces pyroptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma
Graphical abstract
Schematic illustration of the anti-NPC mechanism of lobaplatin in combination with birinapant.
Introduction
Platinum-based combination therapy is recommended by the National Comprehensive Cancer Network (NCCN) as the first-line strategy for nasopharyngeal carcinoma (NPC) chemotherapy [1]. The most commonly used platinum in clinical practice is cisplatin. However, its toxicities, including nephrotoxicity, gastrointestinal upset, myelosuppression, ototoxicity, neurotoxicity and so on, are sometimes unbearable, which seriously affect patient compliance and standardization of the treatment, and might lead to chemoresistance and/or relapse of NPC [2], [3], [4], [5]. Lobaplatin, as one of the third generation platinum, is recognized to have fewer adverse reactions, higher antitumor effect, less platinum cross-resistance, more soluble and stable in water [6], [7]. Nevertheless, the impact of potential dose-limiting thrombocytopenia of lobaplatin on patients still cannot be underestimated [6]. At present, lobaplatin is considered as an effective substitute platinum when cisplatin fails to treat NPC, such as relapse or metastasis [1]. However, its anti-NPC effect has not been compared with cisplatin yet, and its molecular mechanism remains obscure. Additionally, insensitivity of lobaplatin may still exist in some NPC cells. Thus, it is necessary to explore the mechanism of NPC resistance to lobaplatin and find a way to further reduce the dose-dependent toxicity while ensuring its efficacy.
In current study, we demonstrated that lobaplatin induces pyroptosis, an inflammatory programme cell death, through regulating cell inhibitor of apoptosis protein-1/2 (cIAP1/2), Ripoptosome (RIPK1/Caspase-8/FADD) and reactive oxygen species (ROS) in NPC cells. And this anti-NPC effect of lobaplatin was significantly enhanced by birinapant, an antagonist of cIAP1/2 in clinical trials. These findings suggest that birinapant may be used to reduce the toxicity and improve the efficacy of lobaplatin.
Section snippets
Cell lines and reagents
NPC cell lines CNE-1 (catalog #JNO-1856), S26 (catalog #JNO-185), HONE-1 (catalog #JNO-1861), SUNE-1 (catalog #JNO-1860) and CNE-2 (catalog #JNO-1852), and non-tumor immortalized hepatocyte cell line HL-7702 (catalog #JNO-1738) were purchased from Guangzhou Tianjun Biological Technology Co., Ltd. (Guangzhou, GD, China). The cells were cultured in RPMI-1640 (Gibco, Waltham, MA, United States) supplemented with 10% fetal bovine serum (Gibco, Waltham, MA, United States) at 5% CO2 and 37 °C, and
Lobaplatin induces pyroptosis in NPC cell lines
In this study, CCK-8 assay showed that the inhibitory effect of lobaplatin on cell viability of five NPC cell lines is concentration-dependent and time-dependent (Fig. 1a-1e). The IC50 values of lobaplatin in NPC cell lines were lower than that in immortalized hepatocyte cell line HL-7702 (Fig. 1a-1f and Table 1). Flow cytometry demonstrated that lobaplatin causes significant death of NPC cells (Fig. 1g and h). In addition, the activation of caspase-3 and the phosphorylation of H2AX at Ser139
Discussion
Currently, the first-line chemotherapeutic drugs for clinical treatment of NPC are platinums, of which the most commonly used is cisplatin [1]. However, the toxicity and chemoresistance of cisplatin limit its application [2]. By contrast, lobaplatin is less toxic and remains effective for NPCs that relapse or metastasize after cisplatin treatment [6], [7]. In this study, the anti-NPC effect of lobaplatin was similar to that of cisplatin, unconsistent with the clinical report of cervical cancer
Author contributions
Zide Chen, prepared the materials, performed the experiments and analyzed the data, wrote the original draft. Gang Xu, prepared the materials, performed the experiments and analyzed the data. Dong Wu, prepared the materials, performed the experiments and analyzed the data. Shihai Wu, prepared the materials, performed the experiments and analyzed the data. Long Gong, prepared the materials, performed the experiments and analyzed the data. Zihuang Li, performed the experiments and analyzed the
CRediT authorship contribution statement
Zide Chen: Data curation, Methodology, Validation, Funding acquisition, Software, Writing - original draft. Gang Xu: Resources, Methodology. Dong Wu: Resources, Methodology. Shihai Wu: Resources, Methodology. Long Gong: Resources, Methodology. Zihuang Li: Methodology, Data curation. Guanghong Luo: Methodology, Data curation. Jian Hu: Methodology, Data curation. Jian Chen: Methodology, Formal analysis. Xiaoting Huang: Methodology, Formal analysis. Chengcong Chen: Methodology, Formal analysis.
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
This work was supported by grants from the China Postdoctoral Science Foundation (grant numbers 2019M663396) and the Special Foundation for the Development of Strategic Emerging Industries of Shenzhen (grant numbers JCYJ20180228175652675).
Ethics approval
The manuscript did not contain clinical studies or patient data. All animal experiments were approved by the Animal Care and Ethics Committee, and followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978).
References (29)
- et al.
Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response
Radiother. Oncol.
(2019) - et al.
Single-arm, multi-centre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients
Oral Oncol.
(2014) - et al.
A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis
Cancer Lett.
(2016) - et al.
Mechanisms of Gasdermin Family Members in Inflammasome Signaling and Cell Death
J. Mol. Biol.
(2018) - et al.
Gasdermins: Effectors of Pyroptosis
Trends Cell Biol.
(2017) - et al.
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis
Cell
(2007) - et al.
Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
Saudi J. Biol. Sci.
(2018) - et al.
Cisplatin-induced necroptosis in TNFα dependent and independent pathways
Cell. Signal.
(2017) - et al.
J. Natl. Compr. Canc. Netw.
(2017) - et al.
Cisplatin: a review of toxicities and therapeutic applications
Vet. Comp. Oncol.
(2008)